

Page 5, lines 4 and 5, amend subparagraph (E) to read as follows:

1 “(E) to assess and respond to the work-
2 force needs for continuous manufacturing, in-
3 cluding the development of training programs if
4 needed.

Page 6, strike lines 1 through 7 and insert the following paragraphs:

5 “(3) to develop, along with industry partners
6 (which may include large and small biopharma-
7 ceutical manufacturers, generic and nonprescription
8 manufacturers, and contract manufacturers) and an-
9 other institution or institutions designated under
10 this section, if any, a roadmap for developing a con-
11 tinuous manufacturing workforce;

12 “(4) to develop, along with industry partners
13 and other institutions designated under this section,
14 a roadmap for strengthening existing, and devel-
15 oping new, relationships with other institutions; and

16 “(5) to provide an annual report to the Food
17 and Drug Administration regarding the institution’s
18 activities under this section, including a description
19 of how the institution continues to meet and make
20 progress on the criteria listed in subsection (c).

Page 6, line 10, after “funding” insert “, through grants, contracts, or cooperative agreements,”.

Page 6, lines 17 and 18, strike subparagraph (B) (and make such conforming changes as may be necessary).

Page 6, after line 20, insert the following new paragraph (and redesignate the subsequent paragraph accordingly):

1 “(2) CONSISTENCY WITH FDA MISSION.—As a
2 condition on receipt of funding under this sub-
3 section, a National Center of Excellence shall agree
4 to consider any input from the Secretary regarding
5 the use of funding that would—
6 “(A) help to further the advancement of
7 continuous manufacturing through the National
8 Center of Excellence; and
9 “(B) be relevant to the mission of the
10 Food and Drug Administration.

Page 8, line 6, strike “in collaboration with” and insert “in consultation with”.

Page 8, line 17, after “how” insert “advanced manufacturing and”.

Page 8, after line 20, insert the following new subparagraph (and make such conforming changes as may be necessary):

1 “(C) appropriate feedback solicited from
2 the public, which may include other institutions,
3 large and small biopharmaceutical manufactur-
4 ers, generic and nonprescription manufacturers,
5 and contract manufacturers.

Page 8, lines 19 and 20, strike “, review, and approval process for drugs and biological products” and insert “of pharmaceuticals and regulatory responsibilities of the Food and Drug Administration”.

Page 8, after line 21, insert the following new paragraph (and make such conforming changes as may be necessary):

6 “(1) **ADVANCED MANUFACTURING.**—The term
7 ‘advanced manufacturing’ means an approach for
8 the manufacturing of pharmaceuticals that incor-
9 porates novel technology, or uses an established
10 technique or technology in a new or innovative way
11 (such as continuous manufacturing where the input
12 materials are continuously transformed within the
13 process by two or more unit operations) that en-

- 1 enhances drug quality or improves the manufacturing
- 2 process.

Page 8, strike lines 22 through 25 (the “biological product” definition) (and make such conforming changes as may be necessary).

Page 9, strike lines 11 through 13 (the “drug” definition) (and make such conforming changes as may be necessary).

